Abstract:
PURPOSE:The purpose of this study was to evaluate the short-term effects (up to 6 months) of tenofovir disoproxil fumarate (DF) use on renal function in patients being treated for HIV-1 infection. METHOD:The charts of 447 HIV-1-infected patients who received at least three months of tenofovir DF treatment were reviewed. Data collected included demographics, concurrent antiretrovirals, other concurrent medications, CD4 counts and HIV-1 viral loads, and serum creatinine values while on tenofovir DF. Data collection was truncated at 6 months. RESULTS:Baseline serum creatinine (SCr) was 1.0 mg/dL, with a calculated creatinine clearance (CLCr) of 95.2 mL/min (using the Cockroft-Gault equation). There was no significant change in SCr or CLCr at 12 weeks (1.1 mg/dL and 92.7 mL/min, respectively) or 24 weeks (1.1 mg/dL and 92.9 mL/min, respectively). All three patients with grade 2 increases in SCr had other medical reasons for an increased SCr (one patient each had indinavir-associated nephrolithiasis, lactic acidosis, and pancreatitis). No patients experienced any complications from these increases in SCr. CONCLUSION:Increases in SCr and CLCr within the first 6 months of tenofovir DF therapy were rare. Although no clinical nephrotoxicity was observed, continued observation of renal function is warranted in patients predisposed to renal impairment.
journal_name
HIV Clin Trialsjournal_title
HIV clinical trialsauthors
Scott JD,Wolfe PR,Bolan RK,Guyer Bdoi
10.1310/2taj-qpd1-tyae-qak5subject
Has Abstractpub_date
2006-03-01 00:00:00pages
55-8issue
2eissn
1528-4336issn
1945-5771pii
2TAJQPD1TYAEQAK5journal_volume
7pub_type
杂志文章,多中心研究abstract:BACKGROUND:Impaired allostimulatory function of dendritic cells in patients with AIDS has been reported previously. Granulocyte-macrophage colony-stimulating factor (GM-CSF) can restore the T-cell stimulatory function in transforming growth factor-beta 1 (TGF-beta 1)-inhibited murine accessory cells. We now report the ...
journal_title:HIV clinical trials
pub_type: 临床试验,杂志文章
doi:10.1310/HP8B-NF27-VFWA-80YX
更新日期:2002-05-01 00:00:00
abstract:PURPOSE:A comprehensive study comparing the costs and efficacies of darunavir/ritonavir 800/100 mg qd and the other ritonavir-boosted (/r) protease inhibitors (PIs) recommended for treatment-naïve individuals with HIV-1 infection would help health care decision makers identify the value of each boosted PI. METHODS:A c...
journal_title:HIV clinical trials
pub_type: 杂志文章
doi:10.1310/hct1103-133
更新日期:2010-05-01 00:00:00
abstract:PURPOSE:To assess the effect of changing antiretroviral therapy in patients initially treated with saquinavir hard gel capsule (hgc). METHOD:A retrospective cohort study comparing the virological and immunological responses in antiretroviral-naïve patients initially treated with a regimen of saquinavir-hgc, zidovudine...
journal_title:HIV clinical trials
pub_type: 临床试验,杂志文章
doi:10.1310/KED4-8TW3-4ARG-HFC5
更新日期:2001-03-01 00:00:00
abstract:BACKGROUND:The lack of human resources for health is presently recognized as a major factor limiting scale-up of antiretroviral treatment (ART) programs in resourcelimited settings. The mobilization of public and private partners, the decentralization of care, and the training of non-HIV specialist nurses and general p...
journal_title:HIV clinical trials
pub_type: 杂志文章
doi:10.1310/hct0705-255
更新日期:2006-09-01 00:00:00
abstract:PURPOSE:To investigate the factors that contribute to willingness to participate in HIV clinical trials and to determine the impact of a brief intervention on willingness to participate. METHODS:115 consecutive outpatients receiving HIV primary care participated in this prospective study. Each patient completed a ques...
journal_title:HIV clinical trials
pub_type: 杂志文章
doi:10.1310/hct1002-104
更新日期:2009-03-01 00:00:00
abstract:OBJECTIVE:To describe baseline and emergent HIV-1 resistance to elvitegravir/ cobicistat/emtricitabine/tenofovir DF (EVG/COBI/FTC/TDF) and ritonavir-boosted atazanavir/emtricitabine/tenofovir DF (ATV+RTV+FTC/TDF) in HIV-1-infected, treatment-naïve subjects through 144 weeks. METHOD:This was a randomized, double-blind,...
journal_title:HIV clinical trials
pub_type: 杂志文章,随机对照试验
doi:10.1310/hct1505-218
更新日期:2014-09-01 00:00:00
abstract:BACKGROUND:Effective and easy to implement interventions to improve adherence to antiretroviral therapy are needed. OBJECTIVE:To compare site nurse-initiated adherence and symptom support telephone calls for HIV-positive individuals starting antiretroviral therapy to the study site's standard of care. METHODS:A rando...
journal_title:HIV clinical trials
pub_type: 杂志文章,随机对照试验
doi:10.1310/hct1405-235
更新日期:2013-09-01 00:00:00
abstract:PURPOSE:Proven clinical efficacy of protease-sparing regimens (PSR) has been shown. Concerns exist about broad applicability of these regimens in advanced naïve patients. Recent reports have associated a rise in liver enzymes with nevi rapine; however, no data exist with efavirenz. METHOD:17 consecutive antiretroviral...
journal_title:HIV clinical trials
pub_type: 临床试验,杂志文章
doi:10.1310/2V0B-HDWC-AGWR-H56M
更新日期:2001-01-01 00:00:00
abstract:PURPOSE:We obtained peripheral blood monocytes from HIV-1-infected patients and differentiated them into macrophages in vitro to investigate the contribution of purified monocytes to plasma viremia in HIV-infected patients. METHOD:We compared the production of HIV-1 from purified monocytes isolated from patients who w...
journal_title:HIV clinical trials
pub_type: 杂志文章
doi:10.1310/EF26-V3PC-AG5X-FCF4
更新日期:2002-11-01 00:00:00
abstract:BACKGROUND:Some individuals control HIV replication without antiretroviral (ARV) therapy. OBJECTIVE:To analyze viral suppression in young women in rural South Africa enrolled in a trial evaluating a behavioral intervention for HIV prevention. METHODS:Plasma samples were obtained from women ages 13-24 (81 infected at ...
journal_title:HIV clinical trials
pub_type: 杂志文章
doi:10.1080/15284336.2018.1531534
更新日期:2018-10-01 00:00:00
abstract:OBJECTIVE:The efficacy of Product R, a nontoxic peptide-nucleic acid, was tested in 43 HIV-infected adults naïve to antiretroviral therapy. METHOD:Patients were randomized to receive Product R (21 patients) or placebo (22 patients). Dosage was two 1 mL subcutaneous injections daily on days 1-14, followed by 1 mL daily...
journal_title:HIV clinical trials
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.1310/N34A-653T-ABF5-8Q1R
更新日期:2002-07-01 00:00:00
abstract:PURPOSE:To prospectively determine incidence, prevalence, and extent of lipodystrophy (LD) and associated metabolic changes. METHOD:This was a prospective cohort study. Body habitus changes were determined by anthropometrics, photography, and regional dual-energy X-ray absorptiometry (DXA) scan. Metabolic parameters i...
journal_title:HIV clinical trials
pub_type: 杂志文章
doi:10.1310/hct0905-314
更新日期:2008-09-01 00:00:00
abstract:INTRODUCTION:It is not uncommon for patients with HIV infection to miss scheduled visits in outpatient clinics without justifying the failure to appear or reschedule the appointment. Few studies have assessed the impact of inconsistent follow-ups on resource use and disease outcomes in this patient population. OBJECTI...
journal_title:HIV clinical trials
pub_type: 杂志文章
doi:10.1310/hct1305-289
更新日期:2012-09-01 00:00:00
abstract:BACKGROUND:The best method for assessment of functional status in human immunodeficiency virus type 1 (HIV-1) infected persons is unknown. OBJECTIVE:We hypothesized that 3 instruments to assess frailty or disability in elderly populations would perform similarly in HIV-1-infected persons. METHODS:HIV-infected subject...
journal_title:HIV clinical trials
pub_type: 杂志文章
doi:10.1310/hct1306-324
更新日期:2012-11-01 00:00:00
abstract:BACKGROUND:To improve the dosing frequency and pill burden of antiretroviral therapy, we compared two once-daily dosed regimens to a twice-daily dosed regimen. METHOD:HIV-1-infected, antiretroviral drug-naïve adults were randomized to either twice-daily nelfinavir and stavudine and once-daily didanosine (regimen A) or...
journal_title:HIV clinical trials
pub_type: 杂志文章,随机对照试验
doi:10.1310/A686-M37Y-J2PT-E9GJ
更新日期:2005-09-01 00:00:00
abstract:BACKGROUND:Immune response rates following influenza vaccination are often lower in HIV-infected individuals. Low vitamin D levels were correlated with weak immune response in cancer patients and are known to be lower in HIV-infected patients. METHODS:Diagnostic study to determine immune response against the H1N1v com...
journal_title:HIV clinical trials
pub_type: 杂志文章
doi:10.1310/hct1404-175
更新日期:2013-07-01 00:00:00
abstract:PURPOSE:To characterize the steady-state pharmacokinetic combination of the nonpeptidic protease inhibitor tipranavir (TPV) with ritonavir (RTV) in 95 healthy adult volunteers, a phase 1, single-center, open-label, randomized, parallel-group trial was conducted. METHOD:Participants received 250-mg self-emulsifying dru...
journal_title:HIV clinical trials
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.1310/RRX7-49ME-27V7-MWWV
更新日期:2004-11-01 00:00:00
abstract::This article reports noteworthy HIV/AIDS clinical trials presented at the XVth International AIDS Conference, Bangkok, July 2004, and also outlines goals of comprehensive prevention, care, treatment, and monitoring plans. The Bangkok conference theme was "Access for All." Outlined are goals of comprehensive prevention...
journal_title:HIV clinical trials
pub_type:
doi:10.1310/RM35-RE2A-J9L2-8J47
更新日期:2005-01-01 00:00:00
abstract::Tuberculosis and HIV have combined to present a major threat to global public health. Each disease has a negative effect on the other, and mortality in patients with both tuberculosis and HIV is higher than that caused by either condition alone. In regions such as sub-Saharan Africa, as many as a third or more of all ...
journal_title:HIV clinical trials
pub_type: 杂志文章,评审
doi:10.1310/TUNH-UAKU-N0E4-1PXF
更新日期:2001-07-01 00:00:00
abstract:BACKGROUND:Despite the high prevalence of HIV in correctional settings, the duration of therapy and response to various highly active antiretroviral therapy (HAART) regimens in this setting is unknown. METHOD:Using a retrospective cohort study (1997-2002) of HIV-infected prisoners in Connecticut that linked demographi...
journal_title:HIV clinical trials
pub_type: 杂志文章
doi:10.1310/hct0804-205
更新日期:2007-07-01 00:00:00
abstract:OBJECTIVES:Week 96 efficacy and safety of the non-nucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine (RPV) was compared to efavirenz (EFV) in subset of 1,096 subjects who received emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) in pooled data from 2 phase 3 studies. METHODS:ECHO and THRIVE are double...
journal_title:HIV clinical trials
pub_type: 杂志文章,随机对照试验
doi:10.1310/hct1403-81
更新日期:2013-05-01 00:00:00
abstract:BACKGROUND:Multiple resistance to nucleoside analogs mediated by the Q151M complex and/or codon 67-69 inserts/deletions represents a growing problem among HIV-infected persons, most of whom have been exposed to sequential therapies for long periods of time. PATIENTS AND METHOD:All plasma samples collected from HIV-inf...
journal_title:HIV clinical trials
pub_type: 杂志文章
doi:10.1310/X618-KWKJ-WCTQ-LQ2L
更新日期:2003-11-01 00:00:00
abstract::Three HIV individuals with chronic hepatitis C presented with esophageal variceal bleeding. They had mild liver fibrosis and normal liver function tests. All had received didanosine for long periods. Noncirrhotic portal hypertension associated with didanosine may appear in HIV patients without any liver disease or add...
journal_title:HIV clinical trials
pub_type: 杂志文章
doi:10.1310/hct0906-440
更新日期:2008-11-01 00:00:00
abstract:BACKGROUND:Simple antiretroviral drug combinations might provide a comparable benefit to standard triple regimens in patients with mild HIV disease, because poor adherence and toxicities often compromise the sustained benefit of the latest triple regimens, especially when protease inhibitors are used. Bad adherence is ...
journal_title:HIV clinical trials
pub_type: 临床试验,杂志文章,多中心研究
doi:10.1310/FAJF-7A8G-QAR4-Q0X5
更新日期:2002-01-01 00:00:00
abstract:OBJECTIVES:Statins are lipid-lowering drugs that exhibit anti-Inflammatory and immune-modulatory properties, leading to a reduction of serum levels of C-reactive protein (CRP) in the general population. DESIGN:To assess the anti-inflammatory effects of statins in HIV-infected patients, because very limited data are av...
journal_title:HIV clinical trials
pub_type: 杂志文章
doi:10.1310/hct1501-1
更新日期:2014-01-01 00:00:00
abstract:OBJECTIVES:Antiretroviral regimen switching may be considered for HIV-1-infected, virologically-suppressed patients to enable treatment simplification or improve tolerability, but should be guided by knowledge of pre-existing drug resistance. The current study examined the impact of pre-existing drug resistance mutatio...
journal_title:HIV clinical trials
pub_type: 临床试验,杂志文章
doi:10.1080/15284336.2015.1115585
更新日期:2016-02-01 00:00:00
abstract:PURPOSE:To assess the virologic and immunologic response to a boosted double-protease inhibitor (PI) regimen of highly pretreated patients infected with HIV-1 and to examine the role of PI resistance and concentration of serum saquinavir. METHOD:In an open-label prospective study, lopinavir/ritonavir, saquinavir-sgc, ...
journal_title:HIV clinical trials
pub_type: 临床试验,杂志文章
doi:10.1310/HAG3-8YA5-UDQC-36NX
更新日期:2005-03-01 00:00:00
abstract:BACKGROUND:Raltegravir (RAL) constitutes the first available integrase strand transfer inhibitor (INSTI) available in clinical practice. Three independent pathways have been described to confer resistance to RAL. Secondary mutations with little effect on INSTI susceptibility and additional substitutions with an uncerta...
journal_title:HIV clinical trials
pub_type: 杂志文章,多中心研究
doi:10.1310/hct1401-10
更新日期:2013-01-01 00:00:00
abstract::Total eradication of HIV-1 is not yet achievable, in part because reservoirs of latent HIV-1 can develop within lymphoid tissue, the testes, and the central nervous system (CNS). The presence of HIV-1 in the CNS is clinically significant because of its association with the development of HIV dementia, which occurs in ...
journal_title:HIV clinical trials
pub_type: 杂志文章,评审
doi:10.1310/AW2H-TP5C-NP43-K6BY
更新日期:2006-05-01 00:00:00
abstract:OBJECTIVES:ARTEMIS demonstrated significantly greater efficacy of once-daily darunavir/ritonavir (DRV/r) 800/100 mg versus lopinavir/ritonavir 800/200 mg (total daily dose) in treatment-naïve, HIV-1-infected patients at week 96. The influence of baseline characteristics on efficacy and safety was analyzed in DRV/r pati...
journal_title:HIV clinical trials
pub_type: 杂志文章,随机对照试验
doi:10.1310/hct1206-313
更新日期:2011-11-01 00:00:00